A cell death program–based tumor signature stratifies prognosis, immune landscape, and therapeutic response in glioma - Quiz - MDSpire

A cell death program–based tumor signature stratifies prognosis, immune landscape, and therapeutic response in glioma

  • By

  • Zhang, Huaichao

  • Yang, Zijiang

  • Xie, Qiang

  • Chen, Pin

  • Huang, Jinlong

  • Liu, Shuang

  • Li, Zeyang

  • Sun, Wei

  • Zhang, Xiaobiao

  • Xie, Tao

  • May 4, 2026

  • 0 min

Share

Original Source(s)

A cell death program–based tumor signature stratifies prognosis, immune landscape, and therapeutic response in glioma

  • by Zhang, Huaichao , Yang, Zijiang , Xie, Qiang , Chen, Pin , Huang, Jinlong , Liu, Shuang , Li, Zeyang , Sun, Wei , Zhang, Xiaobiao , Xie, Tao

  • May 4, 2026

Related Content

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026

Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma